RetinAI and Boehringer Ingelheim partner over AI treatments for geographic atrophy
Swiss data management software company RetinAI and US-based Boehringer Ingelheim (BI) have announced a partnership to improve patient outcomes in geographic atrophy (GA) with AI. GA is a progressive form of age-related macular degeneration and a leading cause of sight loss.
RetinAI will combine its novel biomarkers analysis Discovery platform and AI tools, with BI’s imaging data sets from clinical studies and real-world evidence in retinal diseases. The companies hope to identify additional, novel biomarkers and predictors of disease progression.
AI can aid in accelerating the development of much-needed novel treatments, and enable earlier and more precise diagnosis of GA.
Dr Carlos Ciller, CEO of RetinAI, commented: “RetinAI is excited to embark on this very important collaboration with BI, a leader in the development of innovative, more precise treatments and application of digital technologies in retinal diseases. Our Discovery platform and novel AI tools in GA accelerate research and provide robust disease insights. We are confident that this collaboration with BI can pave the way to novel treatments that are better tailored to a patient’s disease to transform the lives of people living with retinal diseases.”
Pharmaceutical Industry news, analysis and insights